BR112018013597A2 - composição farmacêutica, método para tratar ou impedir o trabalho de parto prematuro, método para impedir o trabalho de parto antes do parto cesariana, método para tratar ou impedir a dismenorreia e kit - Google Patents

composição farmacêutica, método para tratar ou impedir o trabalho de parto prematuro, método para impedir o trabalho de parto antes do parto cesariana, método para tratar ou impedir a dismenorreia e kit

Info

Publication number
BR112018013597A2
BR112018013597A2 BR112018013597A BR112018013597A BR112018013597A2 BR 112018013597 A2 BR112018013597 A2 BR 112018013597A2 BR 112018013597 A BR112018013597 A BR 112018013597A BR 112018013597 A BR112018013597 A BR 112018013597A BR 112018013597 A2 BR112018013597 A2 BR 112018013597A2
Authority
BR
Brazil
Prior art keywords
preventing
treating
preterm labor
kit
pharmaceutical composition
Prior art date
Application number
BR112018013597A
Other languages
English (en)
Inventor
Naxos Page Patrick
Schwarz Matthias
Jorand-Lebrun Catherine
Quattropani Anna
Pomel Vincent
Loumaye Ernest
Pohl Oliver
Gotteland Jean-Pierre
Original Assignee
ObsEva S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ObsEva S.A. filed Critical ObsEva S.A.
Priority claimed from PCT/EP2017/050099 external-priority patent/WO2017118639A1/en
Publication of BR112018013597A2 publication Critical patent/BR112018013597A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

a invenção fornece composições farmacêuticas compreendendo um composto de fórmula (i) ou (ii) e um agente terapêutico adicional. também é fornecido o sal hcl e a forma cristalina do composto de fórmula (i). o composto inibe o receptor de prostaglandina f (pgf2alfa) e, assim, é útil no tratamento de distúrbios tais como parto prematuro no estágio gestacional inicial.
BR112018013597A 2016-01-04 2017-01-04 composição farmacêutica, método para tratar ou impedir o trabalho de parto prematuro, método para impedir o trabalho de parto antes do parto cesariana, método para tratar ou impedir a dismenorreia e kit BR112018013597A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662274674P 2016-01-04 2016-01-04
US201662395664P 2016-09-16 2016-09-16
US201662407918P 2016-10-13 2016-10-13
PCT/EP2017/050099 WO2017118639A1 (en) 2016-01-04 2017-01-04 Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof

Publications (1)

Publication Number Publication Date
BR112018013597A2 true BR112018013597A2 (pt) 2019-01-08

Family

ID=64734339

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018013597A BR112018013597A2 (pt) 2016-01-04 2017-01-04 composição farmacêutica, método para tratar ou impedir o trabalho de parto prematuro, método para impedir o trabalho de parto antes do parto cesariana, método para tratar ou impedir a dismenorreia e kit

Country Status (3)

Country Link
US (3) US10555934B2 (pt)
CN (1) CN109790133A (pt)
BR (1) BR112018013597A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018013597A2 (pt) 2016-01-04 2019-01-08 ObsEva S.A. composição farmacêutica, método para tratar ou impedir o trabalho de parto prematuro, método para impedir o trabalho de parto antes do parto cesariana, método para tratar ou impedir a dismenorreia e kit
US9447055B1 (en) * 2016-01-04 2016-09-20 Merck Serono S.A. α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
US11534428B1 (en) * 2018-05-16 2022-12-27 Xoma (Us) Llc Compositions and methods for delaying the incidence of labor
EP4243817A1 (en) * 2020-11-16 2023-09-20 Xoma (Us) Llc Compositions and methods for the treatment or prevention of preterm labor
WO2022125876A1 (en) * 2020-12-11 2022-06-16 Olsen Elise A Compositions and methods for inhibiting hair growth

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508045A (en) 1992-10-09 1996-04-16 The Regents Of The University Of California Method and agents for control and management of labor during pregnancy
US5370135A (en) 1993-10-13 1994-12-06 Biex, Inc. Use of estriol measurement to monitor tocolytic therapy
US5872126A (en) * 1996-09-06 1999-02-16 Merck & Co., Inc. Methods and compositions for treating preterm labor
JP2002528500A (ja) * 1998-10-29 2002-09-03 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム チアゾリジンジオン誘導体の早期分娩または授乳期間における子宮収縮を予防するための使用
ZA200406763B (en) 2002-03-28 2005-09-30 Applied Research Systems Thiazolidine carboxamide derivatives as modulatorsof the prostaglandin F receptor.
GB0208785D0 (en) 2002-04-17 2002-05-29 Medical Res Council Treatment methtods
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
BR112016029661A2 (pt) 2014-06-16 2017-08-22 Glaxosmithkline Ip Dev Ltd retosiban para tratamento de parto prematuro
BR112018013597A2 (pt) 2016-01-04 2019-01-08 ObsEva S.A. composição farmacêutica, método para tratar ou impedir o trabalho de parto prematuro, método para impedir o trabalho de parto antes do parto cesariana, método para tratar ou impedir a dismenorreia e kit
US9447055B1 (en) 2016-01-04 2016-09-20 Merck Serono S.A. α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof

Also Published As

Publication number Publication date
US11524003B2 (en) 2022-12-13
US20190000812A1 (en) 2019-01-03
CN109790133A (zh) 2019-05-21
US20230321052A1 (en) 2023-10-12
US20200155515A1 (en) 2020-05-21
US10555934B2 (en) 2020-02-11

Similar Documents

Publication Publication Date Title
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
BR112018013597A2 (pt) composição farmacêutica, método para tratar ou impedir o trabalho de parto prematuro, método para impedir o trabalho de parto antes do parto cesariana, método para tratar ou impedir a dismenorreia e kit
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
CR20140413A (es) Inhibidores de serina/treonina cinasa
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
EA201792619A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
BR112016015236A8 (pt) composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença.
MY193514A (en) Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1, 5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
BR112019007763A2 (pt) composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
BR112017015852A2 (pt) forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
EA201692470A1 (ru) Фармацевтические комбинации
EA201791363A1 (ru) Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]